Esperion Launches Nasal Diuretic for Heart Failure Patients Ahead of CMS Model Shift
Event summary
- Esperion Therapeutics launched ENBUMYST™, a nasal diuretic spray for heart failure patients, ahead of CMS's Ambulatory Specialty Model (ASM) implementation in 2027.
- The nasal spray offers a non-IV, at-home treatment option for managing edema in heart failure patients.
- Esperion is investing in education initiatives targeting clinicians, patients, and healthcare stakeholders.
- The ASM model, launching January 1, 2027, will hold specialty providers accountable for cost and quality of care for Medicare beneficiaries with heart failure.
The big picture
Esperion's launch of ENBUMYST comes as healthcare systems shift towards value-based care models, particularly with CMS's ASM. The nasal diuretic provides a novel administration route that could reduce reliance on IV therapies, aligning with broader trends in decentralized care. With ARCHIMED's backing, Esperion is positioning itself as a key player in cardiometabolic therapies, leveraging its commercial infrastructure to expand market access.
What we're watching
- Regulatory Alignment
- How Esperion's ENBUMYST adoption will align with CMS's ASM model and impact reimbursement dynamics.
- Market Penetration
- The pace at which ENBUMYST gains traction among clinicians and patients as an alternative to IV diuretics.
- Data Generation
- Whether robust data generation activities will support ENBUMYST's long-term use in heart failure treatment.
